ECS Botanics is exploring ways it could enter the US medicinal cannabis market amid reports President Donald Trump is preparing to reclassify cannabis from a schedule 1 to a schedule III drug.
The Victoria-based cultivator said it has initiated a strategic review to assess “potential pathways” should they emerge.
No decision has been made, with ECS stressing that any action is contingent on “regulatory clarity, compliance requirements and disciplined capital allocation”.
Managing director Nan-Maree Schoerie said the company is well placed to take advantage of any future opportunities.
“ECS has deliberately built its business around quality, regulatory compliance and export readiness,” she said. “Our EU-GMP accredited platform and established genetics portfolio provide a strong foundation to assess future opportunities in the US medicinal cannabis market in a disciplined and compliant manner.
“Importantly, ECS is fully funded and operates from a position of balance-sheet strength. This allows us to remain focused on our core Australian and European operations while ensuring we are well positioned to act decisively should compliant US market pathways emerge.”
Despite the potentially positive development, shares in ECS fell 14% to $0.006 cents in Tuesday trading.
The review comes amid speculation that President Trump is pondering reclassifying cannabis, a move that could have wide-ranging implications for the global industry.
Shares in the US spiked last week on the news.
The White House played down any imminent announcement, saying no decision has been made.
Epsilon Healthcare
Epsilon reported a 19% lift in revenue to $3.4 million for the six months to June 30, as the firm emerged from voluntary administration and resumed operational activity.
The manufacturer posted a net loss of $2.1m for the half, up 44% from a $1.4m loss a year earlier, with the firm attributing the result to administrator fees and interest and loan charges associated with funding activities.
Epsilon said the launch of its pharmacy business delivered “better than expected” revenue, while the group reported a rebound in activity following the execution of a Deed of Company Arrangement on June 26, which stabilised its corporate structure.
The group remained suspended from trading on the ASX, with the board continuing remedial work in a bid to resume quotation ahead of a December 18 deadline.
The results come amid ongoing legal proceedings between Epsilon and its former chairman Josh Cui, with the NSW Supreme Court this week ordering the parties to enter mediation in an effort to resolve the dispute.